While a basal level of anti- HER2 Th1 response is reported in healthy individuals, reflective of immune regulation by HER2, suppression of this Th1 response by malignancy breaks the immune protection, ultimately leading to progressive HER2+ tumor development (44, 119). Here, ERBB2 is linked to neoplasm.